This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I wore my Tottenham Hotspur hoodie while shopping at Market Basket last Sunday. One fellow shopper laughed at me. He must have been an Arsenal fan. But another guy commiserated.
If none of this means anything to you, I’m sorry. My favorite soccer team is circling the drain and I feel sad.
The Promise of Erasca’s Pan-RAS Inhibitor
Erasca has been described as the poor man’s Revolution Medicines. While the term "impoverished" doesn’t quite fit—given Erasca’s market value nearing $7 billion—the comparison stems from its focus on developing a better pan-RAS inhibitor for pancreatic cancer. Revolution Medicines, a leader in the space, now boasts a market value exceeding $30 billion, fueling investor interest in identifying the next major biotech breakthrough.
Whether Erasca lives up to the hype will become clearer in May, when the company reports initial results from an early-stage study of its drug, ERAS-0015.
"RevMed has been a real pioneer in this space," said Erasca co-founder and CEO Jonathan Lim during our conversation on Tuesday. "What a day it was last week seeing their data with 13.2 months of median overall survival. It’s great for patients with pancreatic cancer."
Continue to STAT+ to read the full story…
Related articles
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Study Links High Air Pollution to Increased Post-Surgical Complications on Utah’s Wasatch Front
New research on Utah’s Wasatch Front—which occasionally experiences the worst air quality in the nation—has found an association between high air poll...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Why Major Digital Health Companies Are Absent from Medicare’s Chronic Care Pilot Program
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it deli...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...